

Andrew E Moran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8882296/publications.pdf>

Version: 2024-02-01

109
papers

19,167
citations

76322

40
h-index

32838

100
g-index

110
all docs

110
docs citations

110
times ranked

27864
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. <i>Circulation</i> , 2020, 141, e139-e596.	1.6	5,545
2	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468
3	Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. <i>The Lancet Global Health</i> , 2013, 1, e259-e281.	6.3	1,051
4	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2129-2143.	13.7	1,013
5	Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013. <i>Circulation</i> , 2015, 132, 1667-1678.	1.6	717
6	The Global Burden of Ischemic Heart Disease in 1990 and 2010. <i>Circulation</i> , 2014, 129, 1493-1501.	1.6	520
7	Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. <i>Archives of Medical Research</i> , 2015, 46, 328-338.	3.3	486
8	Temporal Trends in Ischemic Heart Disease Mortality in 21 World Regions, 1980 to 2010. <i>Circulation</i> , 2014, 129, 1483-1492.	1.6	454
9	The Global Burden of Disease Study and the Preventable Burden of NCD. <i>Global Heart</i> , 2016, 11, 393.	2.3	343
10	Future Cardiovascular Disease in China. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 243-252.	2.2	305
11	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 743.	7.4	286
12	Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control. <i>Global Heart</i> , 2018, 13, 143.	2.3	246
13	Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the Global Burden of Disease Study 2013: cardiovascular topic. <i>Cardiovascular Journal of Africa</i> , 2015, 26, S6-S10.	0.4	239
14	Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. <i>Hypertension</i> , 2017, 70, 736-742.	2.7	237
15	Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines. <i>New England Journal of Medicine</i> , 2015, 372, 447-455.	27.0	202
16	The Epidemiology of Cardiovascular Diseases in Sub-Saharan Africa: The Global Burden of Diseases, Injuries and Risk Factors 2010 Study. <i>Progress in Cardiovascular Diseases</i> , 2013, 56, 234-239.	3.1	176
17	Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering. <i>Annals of Internal Medicine</i> , 2009, 150, 243.	3.9	157
18	Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 74, 330-341.	2.8	154

#	ARTICLE	IF	CITATIONS
19	A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries. <i>PLoS ONE</i> , 2011, 6, e20821.	2.5	149
20	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 748.	7.4	130
21	The Global Burden of Ischemic Stroke: Findings of the GBD 2010 Study. <i>Global Heart</i> , 2014, 9, 107.	2.3	129
22	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. <i>Hypertension</i> , 2021, 78, 1719-1726.	2.7	117
23	Projected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study. <i>PLoS Medicine</i> , 2016, 13, e1002158.	8.4	116
24	1990-2010 Global Cardiovascular Disease Atlas. <i>Global Heart</i> , 2014, 9, 3.	2.3	108
25	The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. <i>BMC Public Health</i> , 2008, 8, 394.	2.9	85
26	Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group. <i>Journal of the American Heart Association</i> , 2020, 9, e016115.	3.7	75
27	The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. <i>PLoS Medicine</i> , 2015, 12, e1001860.	8.4	72
28	Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. <i>Hypertension</i> , 2020, 75, 973-981.	2.7	72
29	Variations in Ischemic Heart Disease Burden by Age, Country, and Income: The Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. <i>Global Heart</i> , 2014, 9, 91.	2.3	71
30	Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2021, 6, 1406.	6.1	68
31	Left Ventricular Hypertrophy in Mild and Moderate Reduction in Kidney Function Determined Using Cardiac Magnetic Resonance Imaging and Cystatin C: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>American Journal of Kidney Diseases</i> , 2008, 52, 839-848.	1.9	65
32	Assessing the Global Burden of Ischemic Heart Disease: Part 1: Methods for a Systematic Review of the Global Epidemiology of Ischemic Heart Disease in 1990 and 2010. <i>Global Heart</i> , 2012, 7, 315.	2.3	63
33	Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. <i>PLoS ONE</i> , 2016, 11, e0154288.	2.5	60
34	Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016. <i>Circulation</i> , 2021, 144, 271-282.	1.6	58
35	Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals. <i>JAMA Neurology</i> , 2020, 77, 810.	9.0	56
36	São Paulo call to action for the prevention and control of high blood pressure: 2020. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1744-1752.	2.0	53

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Autonomic Neuropathy Is Associated With Microalbuminuria in Older Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 972-977.	8.6	49
38	Potential Cardiovascular and Total Mortality Benefits of Air Pollution Control in Urban China. <i>Circulation</i> , 2017, 136, 1575-1584.	1.6	48
39	Harmonization of Respiratory Data From 9 US Population-Based Cohorts. <i>American Journal of Epidemiology</i> , 2018, 187, 2265-2278.	3.4	46
40	Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005624.	2.2	46
41	Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. <i>Circulation</i> , 2019, 139, 24-36.	1.6	42
42	Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0157036.	2.5	39
43	Scaling up effective treatment of hypertension—A pathfinder for universal health coverage. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1442-1449.	2.0	38
44	The cost-effectiveness of hypertension management in low-income and middle-income countries: a review. <i>BMJ Global Health</i> , 2020, 5, e002213.	4.7	37
45	A Meta-Analysis of Effect of Dietary Salt Restriction on Blood Pressure in Chinese Adults. <i>Global Heart</i> , 2015, 10, 291.	2.3	35
46	Office and Ambulatory Blood Pressure Are Independently Associated With Albuminuria in Older Subjects With Type 2 Diabetes. <i>Hypertension</i> , 2006, 47, 955-961.	2.7	34
47	Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35–74 Years. <i>Hypertension</i> , 2016, 68, 88-96.	2.7	34
48	Cost-effectiveness of Low-density Lipoprotein Cholesterol Level–Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. <i>JAMA Cardiology</i> , 2019, 4, 969.	6.1	30
49	Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. <i>The Lancet Global Health</i> , 2019, 7, e1346-e1358.	6.3	30
50	The clinical utility of apoB versus LDL-C/non-HDL-C. <i>Clinica Chimica Acta</i> , 2020, 508, 103-108.	1.1	27
51	The Global Burden of Cardiovascular Diseases, 1990–2010. <i>Global Heart</i> , 2014, 9, 183.	2.3	27
52	Ischaemic heart disease in the former Soviet Union 1990–2015 according to the Global Burden of Disease 2015 Study. <i>Heart</i> , 2018, 104, 58-66.	2.9	26
53	Cardiovascular Risk Assessment. <i>Medical Clinics of North America</i> , 2017, 101, 673-688.	2.5	25
54	Use of a pooled cohort to impute cardiovascular disease risk factors across the adult life course. <i>International Journal of Epidemiology</i> , 2019, 48, 1004-1013.	1.9	25

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. <i>Circulation</i> , 2021, 143, 2384-2394.	1.6	24
56	Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1954-1964.	2.8	23
57	Nutrition Label Use and Sodium Intake in the U.S.. <i>American Journal of Preventive Medicine</i> , 2017, 53, S220-S227.	3.0	22
58	Projected Impact of Salt Restriction on Prevention of Cardiovascular Disease in China: A Modeling Study. <i>PLoS ONE</i> , 2016, 11, e0146820.	2.5	21
59	Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: The Coronary Heart Disease Policy Model. <i>International Journal of Cardiology</i> , 2011, 150, 332-337.	1.7	18
60	HEARTS in the Americas: a global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. <i>Journal of Human Hypertension</i> , 2023, 37, 126-129.	2.2	18
61	Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. <i>Hypertension</i> , 2019, 74, 267-275.	2.7	16
62	Blood pressure measurement device selection in low-resource settings: Challenges, compromises, and routes to progress. <i>Journal of Clinical Hypertension</i> , 2020, 22, 792-801.	2.0	15
63	Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
64	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1977-1990.	2.8	14
65	Physical Activity and Hypertension From Young Adulthood to Middle Age. <i>American Journal of Preventive Medicine</i> , 2021, 60, 757-765.	3.0	12
66	Moderate-to-vigorous intensity physical activity from young adulthood to middle age and metabolic disease: a 30-year population-based cohort study. <i>British Journal of Sports Medicine</i> , 2022, 56, 847-853.	6.7	12
67	Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. <i>Current Hypertension Reports</i> , 2019, 21, 91.	3.5	11
68	Estimated Prevalence of Masked Asleep Hypertension in US Adults. <i>JAMA Cardiology</i> , 2021, 6, 568.	6.1	11
69	Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study. <i>Global Heart</i> , 2021, 16, 37.	2.3	11
70	Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2022, 145, 1312-1323.	1.6	11
71	Associations of Body Mass Index and Waist Circumference in Young Adulthood with Later Life Incident Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e5011-e5020.	3.6	9
72	Utility of self-reported diagnosis and electrocardiogram Q-waves for estimating myocardial infarction prevalence: an international comparison study. <i>Heart</i> , 2012, 98, 1660-1666.	2.9	8

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2017, 377, 2199-2200.	27.0	8
74	Acculturation is associated with left ventricular mass in a multiethnic sample: the Multi-Ethnic Study of Atherosclerosis. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 161.	1.7	7
75	Cardiovascular Disease Prevention in South Asia: Gathering the Evidence. <i>Global Heart</i> , 2013, 8, 139.	2.3	7
76	Prices of combination medicines and single-molecule antihypertensive medicines in India's private health care sector. <i>Journal of Clinical Hypertension</i> , 2021, 23, 738-743.	2.0	7
77	Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. <i>American Journal of Hypertension</i> , 2016, 29, 1195-1205.	2.0	6
78	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 435-444.	1.7	6
79	Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>Global Heart</i> , 2020, 15, 43.	2.3	6
80	The 2000-2016 WHF Global Atlas of CVD: Take Two. <i>Global Heart</i> , 2020, 13, 139.	2.3	5
81	Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. <i>Biometrics</i> , 2022, 78, 337-351.	1.4	5
82	The U.S. Prevention of Cardiovascular Disease Guidelines and Implications for Implementation in LMIC. <i>Global Heart</i> , 2020, 9, 445.	2.3	5
83	Who does not reduce their sodium intake despite being advised to do so? A population segmentation analysis. <i>Preventive Medicine</i> , 2017, 99, 77-79.	3.4	4
84	Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model in Argentina. <i>Journal of General Internal Medicine</i> , 2017, 32, 524-533.	2.6	4
85	Global cardiovascular disease prevention and management: A collaboration of key organizations, groups, and investigators in low- and middle-income countries. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1293-1295.	2.0	4
86	Low-Density Lipoprotein Cholesterol Trajectories and Prevalence of High Low-Density Lipoprotein Cholesterol Consistent With Heterozygous Familial Hypercholesterolemia in US Children. <i>JAMA Pediatrics</i> , 2021, 175, 1071.	6.2	4
87	Patient-Centered, Sustainable Hypertension Care: The Case for Adopting a Differentiated Service Delivery Model for Hypertension Services in Low- and Middle-Income Countries. <i>Global Heart</i> , 2021, 16, 59.	2.3	4
88	Age, Sex, Race/Ethnicity, and Income Patterns in Ideal Cardiovascular Health Among Adolescents and Adults in the U.S.. <i>American Journal of Preventive Medicine</i> , 2022, 62, 586-595.	3.0	4
89	Predicting Out-of-Office Blood Pressure in a Diverse US Population. <i>American Journal of Hypertension</i> , 2022, 35, 533-542.	2.0	4
90	Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 71-72.	3.0	3

#	ARTICLE	IF	CITATIONS
91	Association Between Ambulatory Blood Pressure and Coronary Artery Calcification: The JHS. Hypertension, 2021, 77, 1886-1894.	2.7	3
92	Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations. Journal of Human Hypertension, 2022, 36, 989-995.	2.2	3
93	Response by Bress et al to Letters Regarding Article, "Potential Cardiovascular Disease Events Prevented With Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline". Circulation, 2019, 139, e1023-e1024.	1.6	2
94	The Retail Outlet Health Kiosk Hypertension Trial (ROKHYT): Pilot Results. American Journal of Hypertension, 2021, , .	2.0	2
95	Factors Associated with Antihypertensive Monotherapy Among US Adults with Treated Hypertension and Uncontrolled Blood Pressure Overall and by Race/Ethnicity, NHANES 2013-2018. American Heart Journal, 2021, , .	2.7	2
96	Hypertension screening, prevalence, treatment, and control at a large private hospital in Kampala, Uganda: A retrospective analysis. PLOS Global Public Health, 2022, 2, e0000386.	1.6	2
97	Cost-effectiveness of masked hypertension screening and treatment in US adults with suspected masked hypertension " a simulation study. American Journal of Hypertension, 0, , .	2.0	2
98	Still on the Road to Worldwide Hypertension Control. Circulation, 2016, 134, 451-454.	1.6	1
99	Secondary Prevention of CVD in LMIC: Care for the Growing Affected Population. Global Heart, 2017, 12, 271.	2.3	1
100	Scorecard for NCDs. Global Heart, 2020, 8, 181.	2.3	1
101	Abstract MP03: The Health And Economic Impact Of Using A Sugar Sweetened Beverage Tax To Subsidize Fruit And Vegetable Purchase In New York City: A Modeling Study. Circulation, 2021, 143, .	1.6	1
102	Response to "Is There Overlap in Blood-pressure Response to the Blockers of the Renin-Angiotensin System Between Lower and Higher Renin Subjects?". American Journal of Hypertension, 2008, 21, 132-132.	2.0	0
103	GW24-e2168"Cost-effectiveness of Improving Acute Myocardial Infarction Treatments and the impact on mortality rate of coronary heart disease in China. Heart, 2013, 99, A127.1-A127.	2.9	0
104	Whom to Treat for High Blood Pressure"Time for a Precision Approach. JAMA Internal Medicine, 2018, 178, 37.	5.1	0
105	Primary Prevention in LMIC: From Population-Based Surveys to Risk Factor Interventions. Global Heart, 2019, 12, 177.	2.3	0
106	Abstract 13699: Cardiovascular Health Impact of Air Pollution Control in Beijing and Urban China: Projections From the Cardiovascular Disease Policy Model-China. Circulation, 2015, 132, .	1.6	0
107	Abstract WP158: Case Fatality and Risk Factor Trend Contributions to Stroke Mortality in Non-Hispanic Blacks and Non-Hispanic Whites, 1999-2012. Stroke, 2016, 47, .	2.0	0
108	Abstract P278: Potential Value of Long-term Intensive BP Treatment in 40-year Patients: A Computer Simulation Study. Circulation, 2017, 135, .	1.6	0

#	ARTICLE	IF	CITATIONS
109	National health and budget impact of implementing the WHO HEARTS hypertension control program in Bangladesh. <i>The Lancet Global Health</i> , 2022, 10, S23.	6.3	0